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Upper-extremity deep venous thrombosis after whole blood
donation: report of three cases from a single blood center
Bruce Newman,1 Madhvi Rajpurkar,2 Bulent Ozgonenel,2 Anup Lal,3 and Philip Kuriakose4
BACKGROUND: There are two upper-extremity deep
venous thrombosis (UEDVT) cases after whole blood
donation reported in the English medical literature.
Three additional UEDVT cases after whole blood
donation were reported to our blood center within a
13-month period.
STUDY DESIGN AND METHODS: A case study was
done for each case in collaboration with a clinical
physician. A description of the donation event, donor
demographics, risk factors for thrombosis, treatment, and
outcome were described.
RESULTS: A 33-year-old woman and two 17-year-old,
first-time-donating men presented with arm pain,
swelling, and bruising within hours to 3 days after
donation. Two had distal UEDVTs in the basilic or
brachial veins, and one had a proximal UEDVT in the
subclavian and axillary veins extending into the basilic
vein. One donor (woman) had known risk factors for DVT
and the other two did not. Anticoagulant therapy was
initiated on all patients and was continued for 3, 4, and 9
months. Two donors with the distal UEDVTs recovered
completely while the donor with the proximal UEDVTwas
treated with anticoagulation for 9 months and continued
to have a slight residual, nonobstructive thrombosis. The
donor was switched to low-dose aspirin prevention. The
two donors reported in the literature had complete
resolution of thrombosis.
CONCLUSIONS: Four of five donors recovered
completely after anticoagulation treatment for UEDVT,
including two of three donors in this study. A review of all
cases in the medical literature, including 20 recent
Australian cases described in an abstract, provides a
more complete description of this adverse donation
injury.
U
pper-extremity deep venous thrombosis
(UEDVT) after whole blood donation is rarely
reported. There are two reported cases in the
English medical literature.1-3 Our institution
had three UEDVT cases after whole blood donation within
a 13-month period. We report the three cases and also
review the two cases reported in the literature. In addition,
we are aware of 20 more cases reported in a recent
abstract from 4.2 million whole blood donations in Aus-
tralia,4 and we report on the abstract.
MATERIALS AND METHODS
Three donation events were reported to American Red
Cross, SE Michigan Region, by the donors, donors’ rela-
tives, or patients’ physician. The blood center medical
director and a third-party hematologist interviewed the
woman donor (Case 1), and hospital and clinic medical
records were also obtained for Case 1. The blood center
medical director collaborated with the patients’ physi-
cians for Cases 2 and 3. American Red Cross records were
obtained for the donations and adverse events.
ABBREVIATIONS: BCP(s) 5 birth control pill(s); INR 5
international normalized ratio; UEDVT 5 upper-extremity
deep venous thrombosis.
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A case study was done for each case in collaboration
with the patient’s physician. A description of the donation
event, donor demographics, risk factors for thrombosis,
treatment, and outcome were described.
RESULTS
Case 1
A 33-year-old Caucasian woman on birth control pills
(BCPs) since 13 years of age donated her fourth whole
blood donation of the year in November 2012 from her
right arm. A needle adjustment was done because of slow
blood flow, and the phlebotomy duration was long, 16
minutes. Three days later the donor telephoned the Amer-
ican Red Cross because of progressive pain, swelling in
her right arm, and a small hematoma (<2 3 2 in.). She
went to an urgent care center 10 days after her donation
because of increasing pain and was referred to a hospital,
and a duplex ultrasound showed acute occlusive DVT in
her proximal brachial vein that extended to the basilic
vein up to the midforearm level. She was treated initially
with enoxaparin and bridged to therapeutic warfarin
(international normalized ratio [INR], 2-3) for approxi-
mately 4 months. Her BCP was changed from an
estrogen-derived BCP (drospirenone-ethinyl estradiol,
Vestura) to a non–estrogen-containing BCP (northin-
drone, Micronor). She recovered completely, and there
was no recurrence. She had a baby in 2013 and two unre-
markable whole blood donations in 2014.
The donor had no previous history of a thrombosis or
coagulopathy. Upon investigation, she was found to be
positive for being a heterozygote for prothrombin gene
variant (G20210A). Factor (F)V Leiden mutation and anti-
phospholipid antibodies were not detected. She had nor-
mal levels for homocysteine and fibrinogen. Her hematol-
ogist felt that the phlebotomy issues contributed to the
pathogenesis of UEDVT. She was considered to be slightly
higher risk for a future thrombosis because of the UEDVT
occurrence, having a heterozygous prothrombin gene var-
iant, and taking a BCP, albeit a nonestrogen BCP. Long-
term anticoagulation was not indicated, and future preg-
nancy was considered to be safe.
Case 2
A 17-year-old, male Caucasian, first-time, high school
donor donated whole blood using his left arm in Decem-
ber 2012. The phlebotomy duration was 10 minutes.
Within hours, he developed swelling and bruising from
the antecubital fossa into the left shoulder. This was asso-
ciated with mild to moderate pain and discoloration of
the skin. The arm partially improved for a day or two and
then the swelling and pain progressed further. The father
telephoned the American Red Cross 5 days after the dona-
tion and was advised to seek urgent care. The donor
presented on the sixth day to a hospital emergency room.
The entire left upper extremity from the elbow to the del-
toid area and into the chest area was swollen with patchy
ecchymoses and prominent veins. A venous Doppler
ultrasound revealed acute extensive occlusive DVT in the
subclavian, axillary, brachial, and basilic veins. The patient
was admitted into the hospital for 5 days. He was started
on intravenous heparin and transitioned to therapeutic
dose warfarin (target INR, 2-3) by the time of hospital dis-
charge. His symptoms resolved rapidly after starting hepa-
rin in the hospital, and swelling and pain decreased by 50-
60% within 24-48 hours after initiation of heparin. His
ultrasound at 6 months still showed considerable clot bur-
den—nonocclusive thrombosis in the subclavian vein,
occlusive thrombosis in the axillary vein, thrombus in the
brachial vein, and superficial thrombus in the cephalic
vein. Warfarin was continued for an additional 3 months
to obtain further improvement, as he had not been com-
pliant with treatment. A repeat ultrasound at 9 months in
October 2013 showed marked improvement, with a small
nonocclusive residual thrombus in the subclavian vein.
The warfarin was stopped, and the donor was placed on
long-term aspirin as a chronic preventative measure
against future thrombosis.5
The donor had no previous history of a thrombosis or
coagulopathy, was a nonsmoker, and was a weightlifter
and athlete. Thrombophilia work-up showed that he was
heterozygous for MTHFR C677T and the 4G mutation in
the tissue plasma activator inhibitor-1.6 Lupus anticoagu-
lant, anti-cardiolipin antibodies, anti-phosphatidylserine
antibodies, and FV Leiden were not detected. He had nor-
mal activities for antithrombin 3, protein C, and protein S.
Case 3
A 17-year-old, male Asian Indian, first-time, high school
donor donated whole blood using his right arm in Decem-
ber 2013. The phlebotomy duration was 6 minutes. The
blood donation was obtained with a good venipuncture,
but the donor complained of a tight tourniquet and hav-
ing to pump his fist throughout the phlebotomy. There
was slight pain during the phlebotomy, which the donor
did not feel was significant. Over the next several days, he
developed pain with arm swelling, bruising, and discolor-
ation in the right upper arm and forearm. At Day 5, physi-
cal examination showed an area of erythema on the
medial aspect of his right arm and forearm measuring
15 cm longitudinally and 5 cm horizontally, with tender-
ness and increased warmth. There was mild pain over the
right biceps muscle and in the antecubital fossa. A venous
Doppler ultrasound showed acute occlusive DVT which
started at the anterior division of the distal right brachial
vein and extended distally. He was prescribed low-
molecular-weight heparin for 3 months. A vascular sur-
geon evaluated him at 3 weeks, and a repeat ultrasound
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showed the thrombus had resolved. The patient stopped
the treatment after 6 weeks on his own. There were no
symptomatic recurrent events.
The donor had no previous history of a thrombosis or
coagulopathy, was a nonsmoker, and was a weightlifter
and cross-country runner. A chest x-ray did not show a
cervical rib, and physical examination maneuvers did not
reveal a thoracic outlet syndrome. Lupus anticoagulant,
cardiolipin antibodies, FV Leiden, and prothrombin
G20210A gene variant mutations were not detected. He
had normal activities for plasminogen, tissue plasminogen
inhibitor, antithrombin, FII, FVIII, protein C, protein S,
and von Willebrand antigen.
DISCUSSION
UEDVTs after whole blood donation are thought to be
rare events, with just two reported cases in the English
medical literature.3 Three reported cases to our institution
in a 13-month period suggests that these cases may be
underreported. A recent abstract from Australia found 20
confirmed UEDVT cases in 4.2 million collections, for an
approximate incidence of one in 211,000.4
The details on the donors in our three cases and on
the two reported in the literature are shown in Table 1.
Donors most commonly presented with progressive arm
pain, arm swelling, and a bruise. Diagnosis of a thrombo-
sis was by ultrasound (four cases) or venogram (one case).
One donor had a proximal venous obstruction in the sub-
clavian and axillary veins that extended into the brachial
and more distal veins. Four donors had distal venous
obstruction in the brachial or basilic or median cubital
veins. The five donors were managed with anticoagulants,
with four reports stating that it was for 3 to 9 months.
Four of the donors had complete resolution of their
thrombi, and in one, the thrombus resolved as early as 3
weeks. The fifth donor with thrombosis in the subclavian
vein had occlusive residual thrombus at 6 months, but it
almost completely resolved by 9 months with better war-
farin compliance. The donor was then switched to aspirin.
An evaluation of our three cases, the two cases in the
literature, and the 20 cases in Australia based on their
abstract provides the most complete description of this
donation adverse event. The Australian abstract on 20
cases reports that all donors had confirmed venous
thromboses after blood donation and were investigated for
thrombotic risk factors.4 Data from an abstract should be
considered to be preliminary data because the final article
may be slightly different. Of the 25 affected donors, 18
(72%) were women, 13 (52%) had a phlebotomy issue, 10
(40%) were on BCPs, and four (16%) had a hereditary gene
variant associated with increased risk for DVT. These risk
factors are not amenable to preventive interventions
because the incidence of the event is rare, and any inter-
vention would lead to very large losses of productive
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donors. Six of 25 donors (24%) had a proximal thrombosis
in the subclavian and/or axillary veins. All of the cases
were managed with anticoagulant treatment. In general,
24 of 25 donors did well with resolution of the thrombus,
no recurrence, and no long-term sequellae. The one
exception was one donor that had residual thrombus at
the end of treatment period (current report) and was
switched to aspirin, but still did well. Another donor had a
pulmonary embolus that resolved (abstract).4
One of our three donors donated two more times
without incident. There are no published data that show
recurrence after a subsequent donation. Therefore, it is
unclear if such donors should be permanently deferred or
not.
An issue is the underreporting of these cases in the
English medical literature. Such cases are reported to the
blood center but may not be recognized because the
blood center does not have a biovigilance system in place,
or it does have a biovigilance system in place, but it does
not recognize such cases as a separate entity. A third pos-
sibility is that the blood center does not realize that such
cases should be reported.
UEDVTs are uncommon and can be classified into
primary (20%) and secondary cases (80%).7 Primary cases
occur because of anatomic abnormalities causing block-
age of venous blood flow, repetitive overexertion of the
arm usually in athletes, or are idiopathic. Secondary cases
of UEDVT occur most commonly after venous cannula-
tion or malignancy. Blood donation would be considered
to be a type of venous cannulation albeit transient. Other
secondary causes are arm surgery, arm trauma, arm
immobilization (plaster cast), and pregnancy. Thrombo-
philic disorders such as FV Leiden mutation, protein C or
S deficiency, prothrombin gene variants, or anti-
phospholipid antibodies can increase the risk of venous
thrombosis but are present in a minority of patients with
UEDVTs.7 Patients present with pain, extremity functional
impairment, paresthesias, swelling and heaviness of the
affected arm, and distended collateral veins. Less than
50% of the patients with these symptoms have an UEDVT
so an ultrasound examination is necessary to confirm the
diagnosis. Treatment consists of anticoagulation with ini-
tial treatment being either a low-molecular-weight hepa-
rin or unfractionated heparin and then bridging to an
anti–vitamin K agent such as warfarin. Treatment is rec-
ommended for at least 3 months and INRs should be
maintained between 2.0 and 3.0. Possible complications
from an UEDVT are postthrombotic syndrome (swelling,
pain, heaviness, venous hypertension, and limb fatigue
with exertion), pulmonary embolism (uncommon), and
recurrent events.
In summary, blood donors that have an UEDVT
appear to do well. Their symptoms consist of pain, swel-
ling, and bruising and start within a few hours to a few
days after blood donation. The donors generally obtained
definitive diagnosis and treatment 5 to 10 days after the
donation. Twenty-five percent had a proximal thrombosis
in the subclavian or axillary vein and 75% had a thrombo-
sis more distally in the brachial or basilic or median cubi-
tal veins. Twenty-four of 25 donors did well after
anticoagulation. None of the donors developed a post-
thrombotic syndrome or any long-term sequellae, but one
donor was placed on long-term aspirin.
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